What is Translational Development Acquisition Corp.'s (TDAC) StockRank?

MoatMap's StockRank for Translational Development Acquisition Corp. (TDAC) is 22/100, with a Sell signal. This is a composite score combining Quality (28), Value (22), and Momentum (58) factor ranks across MoatMap's 20,000+ stock universe.

Does Translational Development Acquisition Corp. have an economic moat?

Translational Development Acquisition Corp. (TDAC) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Translational Development Acquisition Corp. a buy, hold, or sell?

MoatMap's current signal for Translational Development Acquisition Corp. (TDAC) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Translational Development Acquisition Corp. in?

Translational Development Acquisition Corp. (TDAC) operates in the Financial Services sector, specifically the Shell Companies industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TDAC

SELL

Translational Development Acquisition Corp. · Financial Services · United States · $207M · Avg Vol: $274K/d

StockRank

Get insider-trade alerts

P/E (TTM)

38.3x

ROE

3.6%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) established to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. Its competitive positioning relies on the management team's capacity to identify a promising target company within a specific industry. Operating as a non-operating shell entity, its investment appeal stems from its potential to acquire an operating business.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	—	0	0	0	—	—
EPS	—	-0.11	-0.02	0.29	—	0.28
Shares	19.7M	19.7M	21.9M	21.9M	+11.4%	19.3M
Debt	0.3M	0.3M	—	0.2M	-8.3%	0.5M
Equity	-22.1K	-0.5M	168.8M	175.1M	3.8%	—
Op CF	—	-204	-0.9M	-0.6M	—	-0.7M
Inv CF	—	0	-174.2M	0	—	—
Fin CF	—	0	175.5M	0.2M	—	—

Loading 1Y...

PRICE (1Y)+0.7%

SMA 50SMA 200

$10.83

RSI (14)

82.5

52W High

$10.90

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

-0.5%10.2

ROE

3.6%25.0

GP/Assets

—N/A

Op. Margin

0.0%15.1

FCF/Assets

-0.2%20.6

Piotroski

320.3

Int. Cover

—N/A

D/E Ratio

0.00x87.6

Current Ratio

0.09x5.9

Value

P/E (TTM)

38.3x9.7

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

-34.5x25.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

99%93.7

RS 6M

-5%48.8

SMA 50/200

1.01x44.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-10%20.9

FUNDAMENTALS

Market Cap

$207M

P/E (Forward)

—

Gross Margin

—

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of TDAC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TDAC	Translational Development Acquisition Corp.(you)	$207M	22	SELL
GSHR	Gesher Acquisition Corp. II	$214M	23	SELL
CCAQ	Collective Acquisition Corp.	$212M	24	SELL
DYNC	Dynamix Corporation	$239M	21	SELL
ONCH	1RT Acquisition Corp.	$223M	19	STRONG SELL
MACI	Melar Acquisition Corp. I	$236M	19	STRONG SELL
OACC	Oaktree Acquisition Corp. III Life Sciences	$263M	20	SELL
VNME	Vendome Acquisition Corporation I	$254M	25	SELL
DMAA	Drugs Made In America Acquisition Corp.	$260M	25	SELL
NMP	NMP Acquisition Corp.	$164M	19	STRONG SELL

Peer medians: ROE 9.5% · P/E 13.9x · Gross margin 100.0%

Translational Development Acquisition Corp. (TDAC): Stock Score Summary

Translational Development Acquisition Corp. (TDAC) has a MoatMap StockRank of 22/100 based on Quality (28/100), Value (22/100), and Momentum (58/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$10.83
Market Cap	$207M
P/E (TTM)	38.32
Price/Book	-34.50
Return on Equity	3.6%
Return on Invested Capital	-0.5%
Debt/Equity	0.00x
Operating Margin	0.0%
Free Cash Flow	$-353K

Translational Development Acquisition Corp. operates in the Shell Companies industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Translational Development Acquisition Corp.’s (TDAC) StockRank?: MoatMap’s StockRank for Translational Development Acquisition Corp. (TDAC) is 22/100, with a Sell signal. It is a composite of Quality (28), Value (22), and Momentum (58) factor ranks across MoatMap’s 20,000+ stock universe.
Does Translational Development Acquisition Corp. have an economic moat?: Translational Development Acquisition Corp. (TDAC) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Translational Development Acquisition Corp. a buy, hold, or sell?: MoatMap’s current signal for Translational Development Acquisition Corp. (TDAC) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Translational Development Acquisition Corp. in?: Translational Development Acquisition Corp. (TDAC) operates in the Financial Services sector, specifically the Shell Companies industry (United States).